Sousa M M, Saraiva M J
Amyloid Unit, Instituto de Biologia Molecular e Celular and the Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, 4150 Porto, Portugal.
J Biol Chem. 2001 Apr 27;276(17):14420-5. doi: 10.1074/jbc.M010869200. Epub 2001 Jan 24.
Transthyretin (TTR) is a plasma carrier of thyroxine and retinol-binding protein (RBP). Though the liver is the major site of TTR degradation, its cellular uptake is poorly understood. We explored TTR uptake using hepatomas and primary hepatocytes and showed internalization by a specific receptor. RBP complexed with TTR led to a 70% decrease of TTR internalization, whereas TTR bound to thyroxine led to a 20% increase. Different TTR mutants showed differences in uptake, suggesting receptor recognition dependent on the structure of TTR. Cross-linking studies using hepatomas and (125)I-TTR revealed a approximately 90-kDa complex corresponding to (125)I-TTR bound to its receptor. Given previous evidence that a fraction of TTR is associated with high-density lipoproteins (HDL) and that in the kidney, megalin, a member of the low-density lipoprotein receptor family (LDLr) internalizes TTR, we hypothesized that TTR and lipoproteins could share related degradation pathways. Using lipid-deficient serum in uptake assays, no significant changes were observed showing that TTR uptake is not lipoprotein-dependent or due to TTR-lipoprotein complexes. However, competition studies showed that lipoproteins inhibit TTR internalization. The scavenger receptor SR-BI, a HDL receptor, and known LDLr family hepatic receptors did not mediate TTR uptake as assessed using different cellular systems. Interestingly, the receptor-associated protein (RAP), a ligand for all members of the LDLr, was able to inhibit TTR internalization. Moreover, the approximately 90-kDa TTR-receptor complex obtained by cross-linking was sensitive to the presence of RAP. To confirm that RAP sensitivity observed in hepatomas did not represent a mechanism absent in normal cells, primary hepatocytes were tested, and similar results were obtained. The RAP-sensitive TTR internalization together with displacement of TTR uptake by lipoproteins, further suggests that a common pathway might exist between TTR and lipoprotein metabolism and that an as yet unidentified RAP-sensitive receptor mediates TTR uptake.
转甲状腺素蛋白(TTR)是甲状腺素和视黄醇结合蛋白(RBP)的血浆载体。尽管肝脏是TTR降解的主要部位,但其细胞摄取机制尚不清楚。我们利用肝癌细胞和原代肝细胞探索了TTR的摄取,并证明其通过一种特异性受体进行内化。与TTR复合的RBP导致TTR内化减少70%,而与甲状腺素结合的TTR则导致内化增加20%。不同的TTR突变体在摄取方面表现出差异,表明受体识别依赖于TTR的结构。使用肝癌细胞和(125)I-TTR进行的交联研究揭示了一种约90 kDa的复合物,对应于与受体结合的(125)I-TTR。鉴于先前的证据表明一部分TTR与高密度脂蛋白(HDL)相关,并且在肾脏中,低密度脂蛋白受体家族(LDLr)的成员巨蛋白可内化TTR,我们推测TTR和脂蛋白可能共享相关的降解途径。在摄取试验中使用脂质缺乏血清,未观察到显著变化,表明TTR摄取不依赖于脂蛋白或TTR-脂蛋白复合物。然而,竞争研究表明脂蛋白会抑制TTR内化。清道夫受体SR-BI(一种HDL受体)以及已知的LDLr家族肝脏受体在使用不同细胞系统评估时并未介导TTR摄取。有趣的是,受体相关蛋白(RAP)(一种LDLr所有成员的配体)能够抑制TTR内化。此外,通过交联获得的约90 kDa的TTR-受体复合物对RAP的存在敏感。为了确认在肝癌细胞中观察到的RAP敏感性并非正常细胞中不存在的机制,我们对原代肝细胞进行了测试,并获得了类似的结果。RAP敏感的TTR内化以及脂蛋白对TTR摄取的置换,进一步表明TTR和脂蛋白代谢之间可能存在共同途径,并且一种尚未鉴定的RAP敏感受体介导TTR摄取。